Abstract
Goat milk (GM), as compared to cow milk (CM), is easier for humans to digest. It also has antioxidant and anti-inflammatory effects and can improve minor digestive disorders and prevent allergic diseases in infants. It is unclear whether GM consumed in pregnant mothers has any protective effects on allergic diseases in infants. In this experimental study with mice, we found GM feeding enhanced immunoglobulin production, antigen-specific (ovalbumin, OVA) immune responses, and phagocytosis activity. The GM-fed mice had an increasing proportion of CD3+ T lymphocytes in the spleen. Splenocytes isolated from these animals also showed significantly increased production of cytokines IFN-γ and IL-10. More importantly, GM feeding during pregnancy and lactation periods can confer protective activity onto offspring by alleviating the airway inflammation of allergic asthma induced by mite allergens. There was a remarkably different composition of gut microbiota between offspring of pregnant mice fed with water or with milk (GM or CM). There was a greater proportion of beneficial bacterial species, such as Akkermansia muciniphila, Bacteroides eggerthii, and Parabacteroides goldsteinii in the gut microbiota of offspring from GM- or CM-fed pregnant mice compared to the offspring of water-fed pregnant mice. These results suggested that improving the nutrition of pregnant mice can promote immunological maturation and colonization of gut microbiota in offspring. This mother-to-child biological action may provide a protective effect on atopy development and alleviate allergen-induced airway inflammation in offspring.
Keywords: goat milk, immune response, pregnancy, allergic asthma, microbiota
Introduction
An increasing prevalence of allergic diseases, such as atopic dermatitis, allergic rhinitis, and asthma, as well as food allergies, has been noted in western societies (1, 2). Increasing incidences have also been reported in newly developed Asian countries, such as Taiwan (3, 4). These diseases now affect ~20% of the population worldwide (5, 6); yet the prevalence has increased too rapidly in recent decades to be explained by genetic changes alone (1, 5). This increasing incidence of allergic disease alongside a decreasing incidence of microbial infections in western countries has led to the “hygiene hypothesis” (7). This has been updated to encompass the commensal microbiota in early life (8, 9), which is affected by multiple environmental factors, including the mode of delivery during childbirth (10), breast vs. formula feeding (11), a “Western diet” low in fiber and high in fat content (12), and misuse of antibiotics (13).
Several studies show that children who developed allergies later in life have decreased intestinal microbial diversity, particularly lower levels of Bifidobacillus and Lactobacillus species in infancy (14). In addition, the pro-inflammatory metabolites produced by dysbiotic microbiota in the neonatal period have been associated with an increasing atopy risk and T-cell differentiation (15). Although breast milk contains numerous allergy-protective bioactive components, such as milk oligosaccharides, polyunsaturated fatty acids, a variety of cytokines of TGF-β and IL-10, and even microbiota (16), there is conflicting evidence on the protective role of breastfeeding in relation to the development of allergic sensitization and allergic diseases (17). A study conducted by Munblit et al. showed that modulation of human breast milk composition may have the potential to prevent allergic disorders in children (18). Human milk composition varies among individuals, which may explain the heterogeneity of these reports. Although, there is evidence that exclusive breastfeeding for 3–4 months reduces the incidence of eczema and is protective against wheezing in the first 2 years of life, there are no short- or long-term advantages for exclusive breastfeeding beyond 3–4 months that have been demonstrated for preventing atopic disease (19).
Previous studies have suggested that goat milk (GM) is easier for humans to digest than cow milk (CM) because its curds are softer (20, 21). The softer curds of GM may be an advantage for adults suffering from gastrointestinal disturbances and ulcers (21). GM contains higher levels of calcium, magnesium, and phosphorous than those of CM and human milk. The higher levels of medium chain triglycerides (MCT) in GM have been recognized as having unique health benefits for infant nutrition (20, 21). Previous studies have demonstrated antioxidant and anti-inflammatory effects of GM (22). For example, Jirillo et al. have shown that GM modulates human peripheral blood mononuclear cells (PBMCs) and polymorphonuclear neutrophils (PMNs) to produce NO, IL-6, IL-10, and TNF-α (22). It is notable that GM is less immunogenic than CM in a murine model of atopy, where the production of IL-4 was lower and IFN-γ was higher from Concanavalin A (ConA)-stimulated splenocytes of GM-fed mice as compared to those of CM-fed mice (23). However, GM is not recommended in CM allergic patients due to the clinically significant cross-allergenicity between CM and GM (24).
Human breast milk contains more than 80 milk oligosaccharides (HMOs). Because of its prebiotic and anti-infective properties, it has been widely recognized as the major source for early life colonization of gut microbiota in infants (25). Recent studies have shown that GM contains the highest level of oligosaccharides among all domestic animals and has significant similarities to human milk oligosaccharides from a structural point of view (26). Though it is clear that a mother's diet influences the health of her fetus in many ways, there is a lack of concrete evidence to link the role of maternal nutrition to the development of allergic diseases in her infants (17, 19). Whether GM consumption by pregnant mothers has atopy protective effects on their newborns is still unclear. This study first evaluates the immune modulation of GM consumption by maternal mice, then it uses pregnant mice and their offspring to verify this hypothesis.
Materials and Methods
Animals and Diets
Adult, specific pathogen-free, female BALB/c mice (5–6 weeks old), were purchased from the National Laboratory Animal Breeding and Research Center (Tainan, Taiwan). They were housed in plastic cages with an air filter device and maintained on a standard mouse diet (Lab diet; PMI Feeds, St. Louis, MO, USA) in the Laboratory Animal Center of the College of Medicine, National Cheng Kung University. The composition of the standard diet, which consisted of dry pellets (88%), crude protein (18%), crude fat (3.1%), ash (6.2%), fiber (22%), and carbohydrates (35%). All mice were given ad libitum access to deionized water. The GM formula, Mama formulated goat milk (Karihome®), was obtained from Orient EuroPharma Ltd., (Taipei, Taiwan) and manufactured by Dairy Goat Co-operative (NZ) Ltd. (Hamilton, New Zealand). The CM formula was KLIM, powdered milk sold by Nestlé, Switzerland. The GM formula had goat milk protein as the sole protein source, and the CM formula contained cow milk and whey proteins (frequently referred to “whey-enhanced” or “adapted”). In details, the GM formula contained pasteurized goat milk solids (43%), lactose, vegetable oils, minerals, vitamins, acidity regulator (citric acid), choline chloride, L-tryptophan, L-isoleucine, taurine, and L-carnitine. The whey-to-casein ratio was ~20:80, and 60% of the fat was goat milk fat. The CM formula contained cow milk solids (demineralized whey, lactose, skim milk solids, whey solids, and whey protein concentrate), vegetable oils, soy lecithin, minerals, vitamins, acidity regulator (citric acid and/or calcium hydroxide), choline chloride, L-tryptophan, taurine, and L-tyrosine. The whey to casein ratio was ~60:40, and cow fat was not included.
Experiment and Study Designs
All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC No. 105196 and No. 106244). Groups of 12 mice were first used at 6–8 weeks of age. Milk was administered daily to groups of mice by intra-gastric gavage in 200 μL volume. The daily milk intake dose for the mice was calculated from the recommended adult human dose of 25 g/200 mL/60 kg (WHO Dietary recommendations/Nutritional requirements) to 8.5 mg for a 20 g mouse. To evaluate the effect of milk consumption on general immune function, mice were fed with either sterile water (W), GM (low dose 1.6 mg, L; medium dose 8.5 mg, M; and high dose 16.6 mg, H), or CM (8.5 mg; C) for 4 weeks before euthanasia. Mice of control group (N) were fed with normal diet without specific treatment.
To assess the effect of milk consumption on antigen-specific immunological response, groups of mice were fed as described above and were sensitized with an intra-peritoneal (i.p.) injection 50 μg ovalbumin (OVA), 2 μL Complete Freunds Adjuvant (CFA) in 200 μL phosphate-buffered saline (PBS) on day 0, and i.p. [50 μg OVA, 6 μL Incomplete Freunds Adjuvant (IFA) in 200 μL PBS] on day 7. They were then euthanized after 3 weeks. OVA-treated mice were fed with either sterile water (WO), GM (low dose 1.6 mg, LO; medium dose 8.5 mg, MO; and high dose 16.6 mg, HO), or CM (8.5 mg; CO) for 4 weeks before euthanasia. Mice of the control group (N) were fed with normal diet without specific treatment.
To evaluate the effects of milk consumption by pregnant mice on their offspring, the grouping and mating design was depicted in Figure 1. Female mice were intra-gastrically fed (200 μL) with sterile water (group W), GM (8.5 mg, group G), or CM (8.5 mg, group C) (3 mice/group) after they had been paired with male mice. The total feeding period of female mice began from pairing and continued through pregnancy to the end of a 4-week suckling period. At weaning, the offspring mice were randomly divided into two groups—the control group (WN, GN, and CN) and HDM-stimulating group (WA, GA, and CA)—with 10 mice each. To establish the respiratory allergy model in offspring, they were sensitized with HDM allergen Der p (Dermatophagoides pteronyssinus; Allergon, Engelholm, Sweden) on days 0 and 7 by i.p. 200 μL aluminum hydroxide (Al(OH)3) [50 μg Der p/mL Al(OH)3]. Then, mice were intra-nasally (i.n.) delivered by Der p (50 μg/20 μL PBS) daily (5 days). On day 14, mice were challenged with Der p (50 μg/20 μL PBS) by an intra-tracheal (i.t.) route and were sacrificed 2 days later (Figure 1). Control mice were sensitized with PBS (i.p. and i.n.) and were challenged with PBS (i.t.). On the weaning day, offspring mice were marked W0, C0, and G0 individually.
Mouse Antibody and Antigen-Specific Antibody Measurements
IgG1, IgG2a, and IgE ELISA kits were purchased from Bethyl Laboratories (Montgomery, TX, USA) and were used according to the manufacturer's recommended protocol. Antigen (OVA)-specific IgA, IgM, IgG, and IgG subclass antibody titers were measured by using an indirect competitive enzyme-linked immunosorbent assay (ELISA) protocol based on previously described methods (27).
Measurement of Total and Der p-Specific IgE in the Serum
Blood was collected from the cheek facial vein of individual offspring on days 0 and 16. The collected samples were left to stand and clot for 1 h at RT, and they were then centrifuged at 10,000 × g for 30 min to obtain the serum. Serum levels of total and Der p-specific IgE were measured by using an ELISA kit (Mouse IgE ELISA Quantitation Set, E90-115, Bethyl Laboratories, Inc., Montgomery, TX, USA) (28).
Splenocyte Culture and Cytokine Measurement
A cellular suspension was produced by mincing individual spleens between two sterile glass slides. The red blood cells were lysed with ACK Lysing Solution (Catalog number: A1049201, Thermal Fisher Scientific Inc., Waltham, MA, USA), and the splenocytes were extensively washed and re-suspended in RPMI 1640 containing 10% fetal calf serum, 0.1% penicillin, 0.1% streptomycin, and 0.1% glutamine. Cells (5 × 106 cells/mL) were cultured in 24-well plates at 37°C in 5% CO2 and were stimulated with phytohaemagglutinin (1 μg/mL, PHA), ConA (1 μg/mL), or lipopolysaccharide (2 μg/mL, LPS). OVA (10 μg/mL) was used for positive controls and unstimulated cells for background controls. Supernatants were harvested at 48 h and were assayed for the level of IFN-γ, TARC, IL-10, IL-12, and TNF-α concentrations by R&D Systems ELISA (Minneapolis, MN, USA), according to the manufacturer's recommendations. Detection limits were 15 pg/mL for the assays of the abovementioned cytokines.
Passive Cutaneous Anaphylaxis (PCA)
Specific IgE antibody responses to whey proteins were assessed in triplicate by a PCA test in experimental mice. First, 0.1 ml of twofold dilutions of pooled mouse serum samples was intra-dermally injected into ears of recipient mice. All mice were challenged 48 h later by an intravenous injection of 1 ml of 0.9% saline solution containing 5 mg Evans Blue and 2 mg α-lactalbumin or BSA. The reaction was read 30 min after the challenge. The PCA titer was defined as the highest serum dilution when yielding a positive reaction of at least 5 mm in diameter and expressed as means ± SEM (29).
Airway Hyperresponsiveness Measurement
To measure mechanical properties of mice airways, mice were injected (i.p.) with 100 mg/kg of pentobarbiturate, and tracheotomies were performed on day 16 (48 h after Der p i.t. challenge). Lung function was determined by using the Scireq Flexivent apparatus (SCIREQ, Scientific Respiratory Equipment Inc., Montreal, Canada). Mice were treated with increasing doses of acetyl-β-methylcholine chloride (0–5 mg/mL) (A2251, Sigma-Aldrich, St. Louis, MO, USA). Methylcholine was aerosolized for ventilation by using an ultrasonic nebulizer for 3 min separately. Respiratory system resistance (Rrs) and elastance (Ers) were calculated by using flexiVent software and fitting the equation with airway resistance (Rn), tissue elasticity (H), and tissue damping (resistance) (G). The data from each treatment group was used to calculate the average response.
Broncho-Alveolar Lavage Fluid (BALF) and Lung Tissue Examination
The BALF was collected after two times of instillation and aspiration with 1 mL of cold saline into the trachea. BALF was centrifuged at 300 × g for 5 min at 4°C to separate cells and supernatants. The total number of cells in two collections was counted with hemocytometer. Differential cell counts of BALF were performed by cytospin. Cells were stained with Liu's stain solution for microscopic examination, and 200 cells were enumerated. Supernatants were stored at −70°C until assay. To examine the bronchial epithelium inflammation in the lung tissue, lobes were fixed by endotracheal perfusion of alcohol-formalin. After perfusion, the trachea was closed with a suture, and the cardiopulmonary tree was then removed and placed in a 10% neutral buffer formalin (pH 7.4) overnight. Lobes were separated and placed in a cassette for automated paraffin embedding. The paraffin blocks were sectioned into 4–5 μm thickness. Sections were stained with hematoxylin and eosin. Photographs were obtained by a Microscope DP70 (Olympus, Shinjuku, Tokyo, Japan) and DP manager system.
Analysis of Gut Microbiome Composition by Axiom Microbiome Array
Stool samples were obtained from groups of offspring after the weaning period and HDM allergen sensitization (day 0), and offspring were sacrificed after allergen intra-tracheal challenge for 2 days (Day 16). Stool samples were frozen then stored at −80°C. A QIAamp DNA Stool Mini Kit was used to purify DNA from frozen stool samples according to protocol. DNA quality was evaluated using MaestroNano spectrophotometry (Maestrogen, Las Vegas, NV, USA) in absorbance ratio A260 nm/A280 nm. The Affymetrix GeneTitan® platform was used to identify the diversity of the microbiome with a Thermo AxiomTM Microbiome array, which can detect more than 12,000 species of viruses, bacteria, fungi, protozoa, and archaea (30). Initially, the 200 ng target probes were prepared to detect each DNA sample, which contained at least 20 μL of good-quality DNA (10 ng/μL). These samples were then amplified, fragmented, and hybridized on a chip followed by a single-base extension through DNA ligation and signal amplification. The array was scanned automatically on a GeneTitan Multi-Channel instrument according to manufacturer's instructions (Thermo Fisher, Waltham, MA, USA).
Microarray Data Analysis
Microarray data were analyzed using MiDAS software (Axiom Microbial Detection Analysis Software), which is based on the Composite Likelihood Maximization Method (CLiMax) algorithm developed at Lawrence Livermore National Laboratory LLNL (31). Probes with signal intensity above the 99th percentile of random control probe intensities and with more than 20% of target-specific probes detected were considered as positives. The microbiome diversity and difference between different samples were calculated by R language. The principal component assay (PCA) was performed by using Python language.
Statistical Analyses
All analyses were conducted in triplicate. Statistical analysis was performed using GraphPad Prism version 5.0a (GraphPad Software, Inc., La Jolla, CA, USA). Data were analyzed using the Student's t-test, Kruskal-Wallis one-way ANOVA, and the Dunn's post hoc test. If ANOVA assumptions were violated, the Wilcoxon matched-pairs test would be used. Results are expressed as mean ± SEM. Statistical significance was established at the level of p < 0.05.
Results
Goat Milk Intake Modulates Immunological Function of Mice
The effects of GM and CM on nutritional immunity were evaluated in mice fed intragastrically with different types of milk for 4 weeks. Control mice were fed with water only. The body weight of the mice increased steadily over the treatment period (weighed once a week) with no difference among groups fed with water, GM (three dosages; L, M, and H), or CM (C) (data not shown). At the end of the treatment period, there was no difference in spleen weight among the six groups (data not shown). Thus, the daily gavage of mice with GM or CM for 4 weeks did not affect weight gain or spleen size.
In contrast, a significant increase in sera immunoglobulin concentration was observed in mice fed with GM or CM. IgA, IgM, and IgG (total) concentrations were significantly higher in cow milk- and goat milk-fed mice compared to control mice (N) (p < 0.05) (Table 1A). There was a trend of increased IgG2a levels in mice fed with GM, but this was not statistically significant (Table 1A). Splenocyte proliferation in response to mitogens PHA, Con A, and LPS was without difference between milk-fed groups and control group (Table 1B). Nevertheless, supernatants harvested from 24 h culture of splenocytes in GM treatment groups had increasing concentrations of cytokines (Table 1C). Compared to water and CM groups, GM groups (M and H) had a higher level of IFN-γ after LPS stimulation, a higher level of IL-12 after Con A stimulation, and a higher level of TNF-α after PHA or LPS stimulation, particularly with LPS stimulation (Table 1C). A flow cytometry analysis of spleen cells demonstrated that 4 weeks' milk treatment had limited effect on the proportion of helper T cells (CD3+CD4+), cytotoxic T cells (CD3+CD8+), and B cells (CD3−CD45R+). Although there appeared to be a trend of an increase in B cells, it was not significant (Table 1D). NK-cell activity of splenocytes was increased in mice fed with a low dosage of GM compared to control groups (Table 1E). Phagocytic activity was enhanced in mice fed with GM (all dosages) as compared to control and water-fed groups (Table 1F).
Table 1.
Naïve (N) |
Water (W) |
Cow milk (C) |
Goat milk low dose (L) | Goat milk medium dose (M) | Goat milk high dose (H) | |
---|---|---|---|---|---|---|
(A) IMMUNOGLOBULINS | ||||||
IgA (μg/mL) | ||||||
Mean ± SEM | 128.8 ± 8.6 | 156.0 ± 11.9 | 176.3 ± 19.8*a | 207.8 ± 15.5** | 210.7 ± 23.9**a | 211.4 ± 10.5**a |
IgM (μg/mL) | ||||||
Mean ± SEM | 145.9 ± 14.5 | 125.1 ± 27.6 | 271.7 ± 22.2**a | 244.8 ± 24.6**a | 309.2 ± 54.6**a | 28.3 ± 34.0**a |
Total IgG (μg/mL) | ||||||
Mean ± SEM | 27.9 ± 2.9 | 30.3 ± 4.1 | 34.7 ± 4.14*a | 38.8 ± 4.1*a | 48.9 ± 7.3*a | 56.4 ± 11.9*a |
IgG1 (μg/mL) | ||||||
Mean ± SEM | 199.8 ± 26.5 | 167.6 ± 29.1 | 199.1 ± 28.8 | 181.9 ± 29.3 | 165.2 ± 26.1 | 249.1 ± 27.8 |
IgG2a (μg/mL) | ||||||
Mean ± SEM | 9.1 ± 1.7 | 11.3 ± 3.1 | 15.5 ± 4.7 | 24.3 ± 10.6 | 34.4 ± 19.1 | 30.3 ± 10.1 |
(B) SPLEEN CELL PROLIFERATION | ||||||
At 24 h (ratio) | ||||||
PHA/Medium | 1.17 ± 0.08 | 1.14 ± 0.07 | 1.21 ± 0.07 | 1.20 ± 0.09 | 1.22 ± 0.11 | 1.20 ± 0.07 |
Con A/Medium | 1.68 ± 0.27 | 1.32 ± 0.10 | 1.62 ± 0.31 | 1.55 ± 0.17 | 1.61 ± 0.21 | 1.68 ± 0.22 |
LPS/Medium | 1.09 ± 0.06 | 1.10 ± 0.02 | 1.15 ± 0.05 | 1.12 ± 0.03 | 1.15 ± 0.05 | 1.12 ± 0.03 |
At 48 h (ratio) | ||||||
PHA/Medium | 1.31 ± 0.13 | 1.27 ± 0.09 | 1.27 ± 0.07 | 1.36 ± 0.11 | 1.40 ± 0.13 | 1.41 ± 0.10 |
Con A/Medium | 2.33 ± 0.46 | 2.10 ± 0.31 | 2.33 ± 0.32 | 2.92 ± 0.47 | 2.93 ± 0.51 | 3.05 ± 0.45 |
LPS/Medium | 1.17 ± 0.08 | 1.22 ± 0.06 | 1.23 ± 0.07 | 1.19 ± 0.03 | 1.25 ± 0.04 | 1.24 ± 0.05 |
(C) CYTOKINE PRODUCTION | ||||||
IFN-γ (pg/mL) | ||||||
PHA | 117.1 ± 39.6 | 91.0 ± 22.8 | 247.2 ± 67.5 | 227.2 ± 77.4 | 424.4 ± 157.6 | 316.0 ± 103.9 |
Con A | 1504 ± 323.8 | 2121 ± 298.7 | 1695 ± 284.1 | 1891 ± 314.0 | 2192 ± 590.1 | 1900 ± 331.8 |
LPS | 23.6 ± 5.0 | 26.9 ± 3.8 | 25.5 ± 3.5 | 49.7 ± 14.8 | 64.8 ± 20.3*a,*b | 76.7 ± 19.0*a,*b |
IL-12 (pg/mL) | ||||||
PHA | 2.88 ± 0.55 | 2.08 ± 0.67 | 1.81 ± 0.11 | 1.85 ± 0.12 | 1.80 ± 0.19 | 1.85 ± 0.31 |
Con A | 18.85 ± 6.80 | 25.68 ± 4.66 | 27.35 ± 2.40 | 31.81 ± 5.88 | 32.33 ± 6.56*a | 31.50 ± 5.93*a |
LPS | 2.32 ± 0.37 | 2.31 ± 0.50 | 2.04 ± 0.16 | 1.77 ± 0.14 | 1.80 ± 0.17 | 1.55 ± 0.12 |
TNF-α (pg/mL) | ||||||
PHA | 6.93 ± 1.85 | 11.27 ± 2.69 | 10.17 ± 2.67 | 20.67 ± 8.74 | 22.76 ± 5.98*a | 21.59 ± 6.26*a |
ConA | 172.8 ± 22.47 | 216.7 ± 16.26 | 201.7 ± 12.54 | 224.1 ± 21.37 | 208.3 ± 22.91 | 205.1 ± 12.56 |
LPS | 55.17 ± 3.53 | 6.35 ± 3.90 | 59.00 ± 4.80 | 73.48 ± 6.33*a | 79.04 ± 6.72**a,*b | 78.97 ± 4.87**a,**b |
(D) FLOW CYTOMETRY | ||||||
CD3+/CD4+ | 20.40 ± 1.11 | 21.76 ± 1.74 | 25.31 ± 2.33 | 22.80 ± 2.27 | 19.72 ± 0.45 | 21.65 ± 2.96 |
CD3+/CD8+ | 10.64 ± 1.46 | 8.76 ± 1.33 | 9.95 ± 1.49 | 9.72 ± 1.11 | 8.59 ± 1.23 | 7.90 ± 1.14 |
CD3−/CD45R+ | 30.73 ± 4.88 | 33.94 ± 3.99 | 33.91 ± 5.46 | 36.57 ± 4.18 | 38.66 ± 3.76 | 40.75 ± 3.00 |
(E) NK CELL ACTIVITY (%) | ||||||
36.3 ± 7.3 | 42.2 ± 8.3 | 42.2 ± 7.7 | 48.9 ± 8.2*a | 43.8 ± 7.7 | 39.4 ± 5.8 | |
(F) PHAGOCYTOSIS (%) | ||||||
54.8 ± 2.3 | 56.8 ± 1.8 | 59.2 ± 2.1 | 70.7 ± 6.1*a | 69.64 ± 7.2*a | 71.0 ± 14.1*a |
p < 0.05;
p < 0.01.
as compared to control group.
as compared to cow milk-fed group.
Bold values as statistically significance.
Goat Milk Intake Increases Antigen-Specific Immunological Response of Mice
The effects of milk consumption on antigen-specific immunological responses were evaluated by extending the above model with OVA immunization protocol. Mice were immunized on Day 14, boosted on Day 21, and sacrificed on Day 28. As described above, there were no significant differences in body weights or spleen size among different treatment groups. A daily milk gavage did not affect food intake compared to the control groups. The immunization protocol induced an antibody response, with the concentrations of total IgM and IgG being increased in sera from all treatment groups compared to non-immunized group (Table 2A). OVA-specific IgA, IgM, IgG, and IgG subclass antibodies also significantly increased in immunized groups, and there were higher levels of OVA-specific IgA and IgG in mice treated with GM compared to non-milk-fed immunized mice. OVA-specific IgA levels were the highest when feeding with medium dosage of GM (Table 2B). After immunization with an OVA antigen, the proliferation activity of splenocytes increased when cultured with PHA, OVA, and LPS in all immunized groups of mice; neither the milk and non-milk-fed groups nor the GM- and CM-fed groups displayed a significant difference in proliferation activity. The LO group, however, showed significantly decreased cell proliferation at 24 h as compared to the non-milk-fed OVA immunized group (O) (Table 2C).
Table 2.
Naïve (N) |
OVA (O) |
OVA with cow milk (CO) |
OVA with low dose goat milk (LO) |
OVA with medium dose goat milk (MO) |
OVA with high dose goat milk (HO) |
|
---|---|---|---|---|---|---|
(A) TOTAL IMMUNOGLOBULINS | ||||||
IgA (μg/mL) | ||||||
Mean ± SEM | 189.2 ± 19.1 | 236.1 ± 42.4 | 169.7 ± 14.1 | 195.6 ± 24.0 | 205.2 ± 20.9 | 204.7 ± 15.3 |
IgM (μg/mL) | ||||||
Mean ± SEM | 169.6 ± 23.6 | 455.6 ± 60.7*a | 708.4 ± 51.3*a,*b | 770.7 ± 69.6**a,*b | 798.4 ± 132**a,*b | 768.5 ± 61**a,*b |
IgG (μg/mL) | ||||||
Mean ± SEM | 34.3 ± 10.6 | 63.4 ± 18.1 | 99.5 ± 13.8 | 188.6 ± 35.3**a,*c | 203.0 ± 40.5**a,*c | 166.7 ± 15.2**a,*c |
(B) OVA-SPECIFIC IMMUNOGLOBULINS (O.D. 450 nm) | ||||||
Spe IgA | ||||||
Mean ± SEM | 0.02 ± 0.01 | 0.23 ± 0.06 | 0.28 ± 0.04 | 0.28 ± 0.04 | 0.38 ± 0.05*a | 0.26 ± 0.03 |
Spe IgM | ||||||
Mean ± SEM | 0.04 ± 0.01 | 0.91 ± 0.19*a | 1.02 ± 0.10**a | 1.20 ± 0.14**a | 1.17 ± 0.22**a | 0.99 ± 0.14*a |
Spe IgG | ||||||
Mean ± SEM | 0.01 ± 0.01 | 1.76 ± 0.23*a | 2.30 ± 0.06*a | 2.46 ± 0.07**a | 2.46 ± 0.15*a | 2.32 ± 0.12*a |
Spe IgG1 | ||||||
Mean ± SEM | 0.01 ± 0.00 | 2.18 ± 0.23*a | 2.71 ± 0.1**a | 2.60 ± 0.08*a | 2.66 ± 0.15*a | 2.75 ± 0.12**a |
Spe IgG2a | ||||||
Mean ± SEM | 0.01 ± 0.00 | 0.36 ± 0.10 | 0.92 ± 0.29**a,*b | 0.59 ± 0.17*a | 0.51 ± 0.11*a | 0.51 ± 0.09*a |
(C) SPLEEN CELL PROLIFERATION | ||||||
At 24 h | ||||||
PHA/Medium | 1.07 ± 0.04 | 1.38 ± 0.10 | 1.22 ± 0.06 | 1.28 ± 0.09 | 1.28 ± 0.05 | 1.27 ± 0.05 |
OVA/Medium | 1.02 ± 0.01 | 1.21 ± 0.06 | 1.11 ± 0.04 | 1.08 ± 0.02*a | 1.10 ± 0.03 | 1.13 ± 0.02 |
LPS/Medium | 1.04 ± 0.02 | 1.27 ± 0.09 | 1.15 ± 0.07 | 1.14 ± 0.06 | 1.17 ± 0.07 | 1.13 ± 0.04 |
At 48 h | ||||||
PHA/Medium | 1.20 ± 0.08 | 2.46 ± 0.48 | 2.13 ± 0.36 | 1.815 ± 0.31 | 1.98 ± 0.16 | 1.83 ± 0.15 |
OVA/Medium | 0.95 ± 0.01 | 1.30 ± 0.12 | 1.21 ± 0.08 | 1.20 ± 0.08 | 1.17 ± 0.05 | 1.23 ± 0.05 |
LPS/Medium | 1.15 ± 0.09 | 1.46 ± 0.21 | 1.30 ± 0.15 | 1.18 ± 0.10 | 1.21 ± 0.12 | 1.17 ± 0.04 |
(D) CYTOKINE PRODUCTION | ||||||
IFN-γ(pg/mL) 48 h | ||||||
PHA | 543.7 ± 156.4 | 905.1 ± 219.5*a | 838.1 ± 179.3*a | 1214 ± 266.5*a | 1463 ± 255.5*a | 1452 ± 213.2*a*c |
OVA | 4.44 ± 0.41 | 25.57 ± 3.41*a | 37.52 ± 5.67*a | 78.35 ± 19.57*a | 46.34 ± 7.48*a | 48.47 ± 11.88*a |
LPS | 3.81 ± 0.09 | 15.04 ± 5.93 | 95.40 ± 31.14*a | 90.87 ± 30.69*a | 223.9 ± 85.95*a | 338.7 ± 143.1*a |
IL-10 (pg/mL) 48 h | ||||||
PHA | 6.68 ± 2.13 | 17.82 ± 4.16 | 19.53 ± 3.40 | 19.13 ± 6.26 | 23.72 ± 4.11 | 22.15 ± 2.55 |
OVA | 33.6 ± 8.5 | 172.3 ± 20.6 | 239.3 ± 21.1*a | 167.1 ± 45.6 | 204.2 ± 25.5 | 305.9 ± 59.5*a |
LPS | 3.80 ± 0.13 | 3.81 ± 0.12 | 3.99 ± 0.14 | 3.60 ± 0.13 | 3.88 ± 0.15 | 3.80 ± 0.13 |
(E) FLOW CYTOMETRY | ||||||
CD3+(MFI) | 39.62 ± 1.89 | 36.96 ± 1.42 | 34.81 ± 1.47 | 37.70 ± 1.39 | 40.29 ± 1.64*b | 39.81 ± 1.22*b |
CD3+/CD4+ | 17.82 ± 1.34 | 13.37 ± 1.25 | 14.71 ± 1.24 | 15.42 ± 1.77 | 16.70 ± 1.85 | 16.22 ± 1.62 |
CD3+/CD8+ | 14.12 ± 1.20 | 12.43 ± 1.08 | 12.19 ± 0.77 | 12.42 ± 0.57 | 13.16 ± 0.55 | 12.94 ± 0.88 |
CD3−/CD45R+ | 32.45 ± 2.99 | 28.64 ± 2.22 | 29.50 ± 1.34 | 28.89 ± 1.95 | 29.65 ± 2.33 | 29.68 ± 1.68 |
p < 0.05;
p < 0.01.
as compared to control group (N).
as compared to OVA-immunized group (O).
as compared to cow milk-fed (CO) group.
Bold values as statistically significance.
Splenocytes isolated from OVA-immunized mice produced higher levels of IFN-γ and IL-10 after culturing with PHA and OVA antigen than cells from non-immunized mice. When cells were stimulated with LPS, IL-10 production had no difference between these two groups (Table 2D). Levels of IFN-γ had no significant difference between CM-fed and GM-fed OVA-immunized mice when splenocytes were cultured with OVA and LPS. But there was higher IFN-γ production in high-dose GM-fed mice compared to CM-fed mice as cells cultured with PHA. Splenocytes of mice fed with milk (CM and high-dosage GM) secreted higher levels of IL-10 than those of control mice after stimulating with OVA (Table 2D). After immunization with the OVA antigen, mice fed with GM produced a significantly higher amount of total T cells (CD3+) in their spleens, as compared to non-milk- and CM-fed mice (Table 2E). The percentage of other T-cell subpopulations, such as helper T cells(CD3+CD4+) and cytotoxic T cells (CD3+CD8+), and B cells (CD3−CD45R+) in the spleens were not significantly different among the six groups (Table 2E). To assay the recalled antigen immune response, a delayed hypersensitivity reaction for the swelling of mouse ear skin folds was used as described in method section. Supplementary Figure 1A showed that the swelling of the ear skin decreased significantly in GM- and CM-fed mice compared to non-milk-fed mice. A histological examination also showed a significant decrease in epidermis and dermis thicknesses in GM- and CM-fed mice compared to non-milk-fed mice (Supplementary Figure 1B).
Goat Milk Feeding in Pregnant Mice Confers Protection of HDM-Induced Allergic Airway Inflammation in Offspring
To explore the protective effect of GM- or CM-fed pregnant mice on allergen-induced airway inflammation in their offspring, we administrated the maternal group with water, CM, or GM daily from mating until offspring were weaned at 4 weeks of age. Offspring mice were divided into six groups (female and male, n = 6 in each group) according to the maternal mice feeding models. Sensitized (i.p.), intra-nasal (i.n.), and intra-tracheal (i.t.) challenges with HDM (Der p) or with PBS were carried out on the offspring (Figure 1). There was no difference in body weight among the groups of offspring throughout the study (data not shown). The HDM-treated groups (WA, CA, and GA) with exposure to methylcholine induced significantly increasing airway resistance at day 14. However, airway resistance was less severe in GA and CA groups (GA: Rrs, 2.358 cm H2O/mL and Ers, 62.26 cm H2O/mL, CA: Rrs, 2.527 cm H2O/mL and Ers, 85.45 cm H2O/mL) throughout pregnancy and lactation. The decrease in resistance was significant at the concentrations of 2.5 and 5 mg/ml methylcholine inhalation as compared to that of WA group (Rrs, 4.213 cm H2O/mL and Ers, 137.4 cm H2O/mL, p < 0.05) (Figure 2A). In a lung histological examination, non-HDM-sensitized mice (WN, CN, and GN) had minimal inflammatory cell infiltration and lower mucosal thickness (arrow) in the bronchial epithelium than those of HDM-sensitized mice. After being challenged with HDM, GA and CA groups showed significantly decreased inflammatory cell infiltration (12 ± 5 and 7 ± 3 cell/HPF, respectively) and mucosa thickness as compared to those of WA group (35 ± 7 cells/HPF) (Figure 2B).
Further analysis of BALF from HDM-sensitized mice showed that there were increasing numbers of eosinophils, monocytes, and lymphocytes. This confirmed the inflammatory cell infiltration into the lungs. However, BALF from the GA group had lower total cell infiltration levels and fewer numbers of eosinophils compared to those of WA and CA groups (Figure 3A). In mice primed with respiratory allergen (HDM), there were significantly higher levels of total IgE and HDM-specific IgE antibodies than those of non-sensitized mice (Figure 3B). However, the GA group had significantly lower levels of total IgE compared to WA group (p < 0.05). There was a trend of lower levels of Der p-specific IgE antibodies in the GA and CA groups (Figure 3B). Assays of cytokine production in BALF showed lower levels of TARC in the GA group compared to the WA and CA groups (Figure 4A). The levels of TNF-α in BALF were more reduced in HDM-sensitized mice compared to non-HDM-sensitized mice (Figure 4B). There was no significant difference in TNF-α among HDM sensitized and challenged mice. Splenocytes collected from GA group produced the highest levels of IFN-γ following PHA stimulation among the six groups (Figure 4C). Furthermore, splenocytes from GA mice produced significantly higher levels of IL-10 after PHA stimulation as compared to cells from the WA and CA groups of mice (p < 0.05; Figure 4D).
Goat Milk Feeding Induces Gut Microbiota Change in HDM-Sensitized and Challenged Offspring
To analyze gut microbiota among groups of weaned offspring and the effect of gut microbiota on allergen-induced airway inflammation, we collected the stools of the offspring before allergen sensitization (day 0) and 2 days after i.t. allergen challenge (day 16). The detection of the cDNA of stools using Applied Biosystems™ Axiom™ Microbiome Array found the class of Bacteroidia, Clostridia, Flavobacteriia, Bacilli, Deferribacteres, Verrucomicrobiae, and Gammaproteobacteria as well as some unclassified viruses (Table 3). Comparing the ratio of phyla Firmicutes to Bacteroidetes (F/B ratio), the water-fed (W0) group had a higher F/B ratio (0.79) than the GM-fed (G0) (0.50) and CM-fed (C0) groups (0.54) at Day 0. After HDM allergen sensitization and challenge there was a remarkable increase in the F/B ratio in water-fed mice (0.63 in WN vs. 0.84 in WA), while there was no change of F/B ratio in GM-fed (GN vs. GA) and CM-fed mice (CN vs. CA) (Figure 5A). A Weighted Principal Coordinates Analysis (PCoA) for the microbiome of each sample based upon the UniFrac method was performed to compare the overall composition of the bacterial community within the samples (Figure 5B). Gut microbiota of offspring from water-fed mice had a wider spread in PCoA, while offspring from GM- or CM-fed mice, though not overlapping, clustered in the upper left corner of PCoA, suggesting that these gut microbiotas were more abundant and relating to each other. It was also notable that there was no significant change in the abundance and β-diversity in the gut microbiota between non-sensitized and Der p allergen sensitized/challenged offspring from GM- or CM-fed mice, while gut microbiota of offspring from water-fed mice showed greater change in PCoA between WN and WA. The results from heatmap plots showed there were more dominant strains in the gut microbiota of offspring from GM- and CM-fed mice but less in the offspring of water-fed mice (Figure 6). Examples of dominant bacterial strains include Akkermansia muciniphila, Bacteroides eggerthii, and Parabacteroides goldsteinii, which had been reported to be beneficial to human health. In contrast, Coprococcus catus, Lactobacillus murinus, Blautia sp. KLE 1732, and Clostridiales bacterium VE202-09 were found to be dominant in the gut microbiota of offspring from water-fed mice but less in the offspring of GM- or CM-fed mice (Supplementary Figure 2).
Table 3.
Superkingdom | Phylum | Class | D0W | D0G | D0C | D16WN | D16WN | D16GN | D16GA | D16CN | D16CA |
---|---|---|---|---|---|---|---|---|---|---|---|
Bacteria | Bacteroidetes | Bacteroidia | 45 | 47 | 45 | 45 | 44 | 46 | 45 | 46 | 46 |
Bacteria | Firmicutes | Clostridia | 30 | 25 | 23 | 24 | 33 | 24 | 24 | 26 | 23 |
Bacteria | Bacteroidetes | Flavobacteriia | 3 | 3 | 3 | 3 | 1 | 2 | 3 | 3 | 3 |
Bacteria | Firmicutes | Bacilli | 8 | 0 | 3 | 6 | 5 | 2 | 0 | 0 | 0 |
Bacteria | Deferribacteres | Deferribacteres | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Bacteria | Verrucomicrobia | Verrucomicrobiae | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Bacteria | Proteobacteria | Gammaproteobacteria | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Viruses | Unclassified | Unclassified | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
Discussion
Bioactive compounds presenting in food are called nutraceuticals or functional foods. They are beneficial to the human body in many aspects and may go beyond their nutritional roles. Goat milk contains several bioactive compounds that might be useful in relieving cardiovascular disease, metabolic disorders, neurological degeneration, and promoting the establishment of intestinal microbiotas (32). In host immunity, when pathogens invade human body, B cells will generate antibodies to target specific antigens (33). Casein phosphopeptides of GM can increase the level of IgA in stool, which suggests a positive effect on mucosal immunity. Lactoferrin in GM has been demonstrated to play an important role in increasing the activity of NK cells and increasing the phagocytic activity of phagocytes (34). GM can also trigger IL-10, TNF-α, and IL-6 production in blood cells (35).
Our results showed that GM-fed mice could enhance the immune response in antibody production (IgA, IgM, and IgG subclasses) and phagocytosis activity promotion. Compared to CM-fed mice, there were more IFN-γ, IL-12, and TNF-α cytokine production in the culture supernatant of stimulated splenocytes in GM-fed mice. When mice were immunized with a specific antigen (OVA), GM-fed mice, but not CM-fed mice, had more antigen-specific antibodies (IgA, IgM, IgG, and IgG subclasses) than water-fed mice. There was a significant increase in IFN-γ and IL-10 production in the culture supernatant of stimulated splenocytes as well as an increase in the amount of CD3+ T lymphocytes in GM-fed mice. More importantly, we found these enhancements of the immune response in innate and adaptive immunities in pregnant mice; mice fed with GM in particular could pass immunity to their offspring to alleviate allergen-induced airway inflammation of allergic asthma. These offspring from pregnant mice fed with GM or CM showed a drastic change of gut microbiota composition after weaning, compared to offspring of water-fed mice. We suspected that GM feeding during pregnancy and lactation might change the composition of breast milk and confer immunological maturation and colonization of gut microbiota on offspring, and this might suppress atopy development and downregulate airway inflammation.
Relationships among a wide spectrum of bioactive factors, such as proteins, polyunsaturated fatty acids, oligosaccharides, microbial content, metabolites, and micronutrients present in breast milk and allergy development in infants have attracted more attention (36–39). Various maternal exposures during pregnancy, such as immunization, dietary patterns, vitamin D, omega-3 fatty acids, and/or probiotics may affect breast milk composition and thereby influence the early colonization of gut microbiota and infant health (16, 40). Early microbial colonization is essential to infants' metabolic and immunological development (41). There is a direct link between microbial colonization and the risk of non-communicable diseases in later life, including allergies (42). After birth, the transfer of microbiota continues during lactation, and it is considered as the cause of differences in gut microbiota between exclusively breast-fed and formula-fed infants during the first month of life (43). In clinical trials, oral administration of bacterial strains to lactating mothers modulated both human milk composition and infant's gut microbiota. For instance, intake of Lactobacillus reuteri led to its detection in the mother's milk and infant stool (44). Another study found that giving Lactobacillus rhamnosus to mothers during pregnancy and lactation can reduce the risk of allergy development (45). Probiotic intake during pregnancy and lactation also induced specific changes in infant Bifidobacterium colonization and affected breast milk microbiota composition, oligosaccharides, and lactoferrin (46).
While it is clear that mother's diet influences the health of her fetus, there is currently no concrete evidence in the role of maternal nutrition and the development of allergic diseases in children. As compared to formula feeding, there is clear evidence that breastfeeding can increase gut microbial biodiversity in infants. Whether GM consumption during pregnancy and lactation can induce changes of intestinal microbiota in newborns has never been explored. One clinical study (47) was conducted to compare the composition of the stool microbiotas of infants (<2 years old) fed with GM formula, CM-based formula, or breast milk. The results of the beta-diversity analysis showed that gut microbiotas and Lachnospiraceae populations were more similar between breast/goat milk comparisons than those between breast/cow milk comparisons. This similarity appeared to be based on the predominance of Ruminococcus gnavus among Lachnospiraceae in breast/goat milk-fed microbiotas. Our study showed there were significant differences in the intestinal microbiota compositions (PCoA analysis) and decreased Firmicutes/Bacteroidetes (F/B) ratio in the offspring of GM- or CM-fed pregnant mice compared to those offspring of water-fed mice. Besides, allergen sensitization and challenge induced slight changes in the composition of gut microbiota and F/B ratio in offspring of milk-fed mice, in contrast to the wide swings of change in the offspring of water-fed mice. These results were consistent with previous research that the resilient characteristics and atopy-protective role of colonized gut microbiota could confer from milk-fed maternal mice to their offspring during pregnancy and lactation periods (48).
The abundance of bacterial species, such as A. muciniphila and P. goldsteinii, in the offspring's gut microbiota of GM- or CM-fed mice had multiple regulatory functions on glucose metabolism in diabetes and obesity as well as anti-inflammatory action in inflammatory bowel diseases (49–51). Bacteroides eggerthii and Bacteroides fragilis were reported to be associated with propionate production in human intestine (52). Propionate is a short-chain fatty acid and is suggested to be associated with IL-10-producing regulatory T (Treg)-cell differentiation in gut-associated lymphoid tissues (53). Recently, it had been found that there were reduced A. muciniphila and Faecalibacterium prausnitzii levels in the intestinal microbiota of children with allergic asthma (54), which might explain the anti-asthma protective role of GM-fed offspring with increasing levels of A. muciniphila in their gut microbiota.
In conclusion, this study showed that GM consumption could enhance immune function and antigen-specific immune response in mice. Furthermore, maternal GM consumption during pregnancy and lactation periods could affect the composition of gut microbiota in offspring and protected them against atopy and allergen-induced airway inflammation (Supplementary Figure 3). We believe these findings have important clinical implications in the improvement the nutrition of pregnant mothers and components of their breastmilk. Future trials are needed to prove this concept in order to promote maternal health and perinatal nutrition and to reduce allergic diseases in infants.
Data Availability Statement
The microarray data has been uploaded to the GEO—GSE144086. Other raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
Ethics Statement
The animal study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC No. 105196, and No. 106244), College of Medicine, National Cheng Kung University.
Author Contributions
H-FK, Y-CW, and H-YT conducted the experiments of the immunological studies. H-FK, M-HH, and P-CC conducted the experiment of the mouse model of allergic asthma. LW, L-FL, and H-JT for microbiota assays, bio-information, and statistics analysis. W-SK and Z-GL for technical advice. H-FK and J-YW for experimental design and writing up manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
Authors would like to thank Dr. Elizabeth (Liz) Carpenter's critical proofreading and suggestions for this manuscript.
Footnotes
Funding. This research work was supported by the Center for Allergy and Clinical Immunology Research (ACIR), Research and Service Headquarter, and in part by the Headquarters of University Advancement, National Cheng Kung University, Tainan, Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. There was no additional external funding received for this study.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.00184/full#supplementary-material
References
- 1.Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. (2017) 140:1–12. 10.1016/j.jaci.2017.05.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Murrison LB, Brandt EB, Myers JB, Hershey GKK. Environmental exposures and mechanisms in allergy and asthma development. J Clin Invest. (2019) 129:1504–15. 10.1172/JCI124612 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Wang JY, Liu LF. Health care utilization and medical costs for childhood asthma in Taiwan: using Taiwan National Health Insurance Research Database. Asia Pac Allergy. (2012) 2:167–71. 10.5415/apallergy.2012.2.3.167 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Wu LS-S, Sjakste T, Sakalauskas R, Sitkauskiene B, Paramonova N, Gasiuniene E, et al. The burden of allergic asthma in children: a landscape comparison based on data from Lithuanian, Latvian, and Taiwanese populations. Pediatr Neonatol. (2012) 53:276–82. 10.1016/j.pedneo.2012.08.001 [DOI] [PubMed] [Google Scholar]
- 5.Platts-Mills TA. The allergy epidemics: 1870–2010. J Allergy Clin Immunol. (2015) 136:3–13. 10.1016/j.jaci.2015.03.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pearce N, Ait Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. (2007) 62:758–66. 10.1136/thx.2006.070169 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Strachan DP. Hay fever, hygiene, and household size. BMJ. (1989) 299:1259–60. 10.1136/bmj.299.6710.1259 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Reynolds LA, Finlay BB. Early life factors that affect allergy development. Nat Rev Immunol. (2017) 17:518–28. 10.1038/nri.2017.39 [DOI] [PubMed] [Google Scholar]
- 9.Ege MJ. The hygiene hypothesis in the age of the microbiome. Ann Am Thorac Soc. (2017) 14(Suppl_5):S348–53. 10.1513/AnnalsATS.201702-139AW [DOI] [PubMed] [Google Scholar]
- 10.Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. (2010) 107:11971–5. 10.1073/pnas.1002601107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Praveen P, Jordan F, Priami C, Morine MJ. The role of breast-feeding in infant immune system: a systems perspective on the intestinal microbiome. Microbiome. (2015) 3:41. 10.1186/s40168-015-0104-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound over generations. Nature. (2016) 529:212–5. 10.1038/nature16504 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wang JY, Liu LF, Chen CY, Huang YW, Hsiung CA, Tsai HJ. Acetaminophen and/or antibiotic use in early life and the development of childhood allergic diseases. Int J Epidemiol. (2013) 42:1087–99. 10.1093/ije/dyt121 [DOI] [PubMed] [Google Scholar]
- 14.Cahenzli J, Köller Y, Wyss M, Geuking MB, McCoy KD. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. (2013) 14:559–70. 10.1016/j.chom.2013.10.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. (2016) 22:1187–91. 10.1038/nm.4176 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.D'Alessandro A, Scaloni A, Zolla L. Human milk proteins: an interactomics and updated functional overview. J Prot Res. (2010) 9:3339–73. 10.1021/pr100123f [DOI] [PubMed] [Google Scholar]
- 17.Munblit D, Peroni DG, Boix-Amoros A, Hsu PS, Van't Land B, Gay MCL, et al. Human milk and allergic diseases: an unsolved puzzle. Nutrients. (2017) 9:E894. 10.3390/nu9080894 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Munblit D, Boyle RJ, Warner JO. Factors affecting breast milk composition and potential consequences for development of the allergic phenotype. Clin Exp Allergy. (2015) 45:583–601. 10.1111/cea.12381 [DOI] [PubMed] [Google Scholar]
- 19.Greer FR, Sicherer SH, Burks AW. The Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods. Pediatrics. (2019) 143:e20190281. 10.1542/peds.2019-0281 [DOI] [PubMed] [Google Scholar]
- 20.Zenebe T. Review on medicinal and nutritional values of goat milk. Acad J Nutr. (2014) 3:30–9. 10.5829/idosi.ajn.2014.3.3.93210 [DOI] [Google Scholar]
- 21.Zhou SJ, Sullivan T, Gibson RA, Lonnerdal B, Prosser CG, Lowry DJ, et al. Nutritional adequacy of goat milk infant formulas for term infants: a double-blind randomised controlled trial. Br J Nutr. (2014) 111:1641–51. 10.1017/S0007114513004212 [DOI] [PubMed] [Google Scholar]
- 22.Jirillo F, Magrone T. Anti-inflammatory and anti-allergic properties of donkey's and goat's milk. Endocr Metab Immune Disord Drug Targets. (2014) 14:27–37. 10.2174/1871530314666140121143747 [DOI] [PubMed] [Google Scholar]
- 23.Lara-Villoslada F, Olivares M, Jimenez J, Boza J, Xaus J. Goat milk is less immunogenic than cow milk in a murine model of atopy. J Pediatr Gastroenterol Nutr. (2004) 39:354–60. 10.1097/00005176-200410000-00010 [DOI] [PubMed] [Google Scholar]
- 24.Hazebrouck S, Ah-Leung S, Bidat E, Paty E, Drumare MF, Tilleul S, et al. Goat's milk allergy without cow's milk allergy: suppression of non-cross-reactive epitopes on caprine beta-casein. Clin Exp Allergy. (2014) 44:602–10. 10.1111/cea.12261 [DOI] [PubMed] [Google Scholar]
- 25.Jost T, Lacroix C, Braegger C, Chassard C. Impact of human milk bacteria and oligosaccharides on neonatal gut microbiota establishment and gut health. Nutr Rev. (2015) 73:426–37. 10.1093/nutrit/nuu016 [DOI] [PubMed] [Google Scholar]
- 26.Kiskini A, Difilippo E. Oligosaccharides in goat milk: structure, health effects and isolation. Cell Mol Biol. (2013) 59:25–30. 10.1170/T944 [DOI] [PubMed] [Google Scholar]
- 27.Kohl TO, Ascoli CA. Indirect competitive enzyme-linked immunosorbent assay (ELISA). Cold Spring Harbor Protocols. (2017) 2017:pdb.prot093757. 10.1101/pdb.prot093757 [DOI] [PubMed] [Google Scholar]
- 28.Chen PC, Hsieh MH, Kuo WS, Kao HF, Hsu CL, Wang JY. Water-soluble chitosan inhibits nerve growth factor and attenuates allergic inflammation in mite allergen-induced allergic rhinitis. J Allergy Clin Immunol. (2017) 140:1146–9.e8. 10.1016/j.jaci.2017.03.022 [DOI] [PubMed] [Google Scholar]
- 29.Evans H, Killoran KE, Mitre E. Measuring local anaphylaxis in mice. J Vis Exp. (2014) 92:e52005 10.3791/52005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Thissen JB, Be NA, McLoughlin K, Gardner S, Rack PG, Shapero MH, et al. Axiom Microbiome Array, the next generation microarray for high-throughput pathogen and microbiome analysis. PLoS ONE. (2019) 14:e0212045. 10.1371/journal.pone.0212045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.McLoughlin KS. Microarrays for pathogen detection and analysis. Brief Funct Genom. (2011) 10:342–53. 10.1093/bfgp/elr027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Lima MJ, Teixeira-Lemos E, Oliveira J, Teixeira-Lemos L, Monteiro A, Costa M. Nutritional and health profile of goat products: focus on health benefits of goat milk. In: Kukovics S, editor. Goat Science. IntechOpen; (2018). p. 189–232. 10.5772/intechopen.70321 [DOI] [Google Scholar]
- 33.Kitamura H, Otani H. Fecal IgA levels in healthy persons who ingested cakes with or without bovine casein phosphopeptides. Milchwissenschaft. (2002) 57:611–4. [Google Scholar]
- 34.Kanwar JR, Roy K, Patel Y, Zhou SF, Singh MR, Singh D, et al. Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions. Molecules. (2015) 20:9703–31. 10.3390/molecules20069703 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Jirillo F, Martemucci G, D'Alessandro AG, Panaro MA, Cianciulli A, Superbo M, et al. Ability of goat milk to modulate healthy human peripheral blood lymphomonocyte and polymorphonuclear cell function: in vitro effects and clinical implications. Curr Pharm Design. (2010) 16:870–6. 10.2174/138161210790883534 [DOI] [PubMed] [Google Scholar]
- 36.Sprenger N, Odenwald H, Kukkonen AK, Kuitunen M, Savilahti E, Kunz C. FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk. Eur J Nutr. (2017) 56:1293–301. 10.1007/s00394-016-1180-6 [DOI] [PubMed] [Google Scholar]
- 37.Logan CA, Brandt S, Wabitsch M, Brenner H, Wiens F, Stahl B, et al. New approach shows no association between maternal milk fatty acid composition and childhood wheeze or asthma. Allergy. (2017) 72:1374–83. 10.1111/all.13161 [DOI] [PubMed] [Google Scholar]
- 38.Waidyatillake NT, Stoney R, Thien F, Lodge CJ, Simpson JA, Allen KJ, et al. Breast milk polyunsaturated fatty acids: associations with adolescent allergic disease and lung function. Allergy. (2017) 72:1193–201. 10.1111/all.13114 [DOI] [PubMed] [Google Scholar]
- 39.Seppo AE, Autran CA, Bode L, Jarvinen KM. Human milk oligosaccharides and development of cow's milk allergy in infants. J Allergy Clin Immunol. (2017) 139:708–11.e5. 10.1016/j.jaci.2016.08.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Munblit D, Verhasselt V. Allergy prevention by breastfeeding: possible mechanisms and evidence from human cohorts. Curr Opin Allergy Clin Immunol. (2016) 16:427–33. 10.1097/ACI.0000000000000303 [DOI] [PubMed] [Google Scholar]
- 41.Bendiks M, Kopp MV. The relationship between advances in understanding the microbiome and the maturing hygiene hypothesis. Curr Allergy Asthma Rep. (2013) 13:487–94. 10.1007/s11882-013-0382-8 [DOI] [PubMed] [Google Scholar]
- 42.Bridgman SL, Kozyrskyj AL, Scott JA, Becker AB, Azad MB. Gut microbiota and allergic disease in children. Ann Allergy Asthma Immunol. (2016) 116:99–105. 10.1016/j.anai.2015.10.001 [DOI] [PubMed] [Google Scholar]
- 43.Guaraldi F, Salvatori G. Effect of breast and formula feeding on gut microbiota shaping in newborns. Front Cell Infect Microbiol. (2012) 2:94. 10.3389/fcimb.2012.00094 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Abrahamsson TR, Sinkiewicz G, Jakobsson T, Fredrikson M, Björkstén B. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. J Pediatr Gastroenterol Nutr. (2009) 49:349–54. 10.1097/MPG.0b013e31818f091b [DOI] [PubMed] [Google Scholar]
- 45.Gueimonde M, Sakata S, Kalliomaki M, Isolauri E, Benno Y, Salminen S. Effect of maternal consumption of Lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr. (2006) 42:166–70. 10.1097/01.mpg.0000189346.25172.fd [DOI] [PubMed] [Google Scholar]
- 46.Mastromarino P, Capobianco D, Miccheli A, Pratico G, Campagna G, Laforgia N, et al. Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacol Res. (2015) 95-96:63–70. 10.1016/j.phrs.2015.03.013 [DOI] [PubMed] [Google Scholar]
- 47.Tannock GW, Lawley B, Munro K, Gowri Pathmanathan S, Zhou SJ, Makrides M, et al. Comparison of the compositions of the stool microbiotas of infants fed goat milk formula, cow milk-based formula, or breast milk. Appl Environ Microbiol. (2013) 79:3040–8. 10.1128/AEM.03910-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. (2009) 9:123. 10.1186/1471-2180-9-123 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol. (2017) 8:1765. 10.3389/fmicb.2017.01765 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. (2017) 106:171–81. 10.1016/j.micpath.2016.02.005 [DOI] [PubMed] [Google Scholar]
- 51.Wu TR, Lin CS, Chang CJ, Lin TL, Martel J, Ko YF, et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis. Gut. (2019) 68:248–62. 10.1136/gutjnl-2017-315458 [DOI] [PubMed] [Google Scholar]
- 52.Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, et al. Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis. PLoS ONE. (2018) 13:e0203657. 10.1371/journal.pone.0203657 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Dao Nguyen X, Robinson DS. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol. (2004) 114:296–301. 10.1016/j.jaci.2004.04.048 [DOI] [PubMed] [Google Scholar]
- 54.Demirci M, Tokman HB, Uysal HK, Demiryas S, Karakullukcu A, Saribas S, et al. Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. Allergol Immunopathol. (2019) 47:365–71. 10.1016/j.aller.2018.12.009 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The microarray data has been uploaded to the GEO—GSE144086. Other raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.